Data from Chondrolectin Is a Novel Diagnostic Biomarker and a Therapeutic Target for Lung Cancer

• DOI: 10.1158/1078-0432.c.6521201.v1
• Publication Date: 2023-04-01T06:55:04Z
• Authors: Ken Masuda; Atsushi Takano; Hideto Oshita; Hirohiko Akiyama; Eiju Tsuchiya; Nobuoki Kohno; Yusuke Nakamura; Yataro Daigo

<div>Abstract<p><b>Purpose:</b> This study aims to identify molecules that might be useful as diagnostic/prognostic biomarkers and as targets for the development of new molecular therapies for lung cancer.</p><p><b>Experimental Design:</b> We screened for genes that were highly transactivated in a large proportion of 120 lung cancers by means of a cDNA microarray representing 27,648 genes and found chondrolectin (<i>CHODL</i>) as a candidate. Tumor tissue microarray was applied to examine the expression of CHODL protein and its clinicopathologic significance in archival non–small cell lung cancer (NSCLC) tissues from 295 patients. A role of CHODL in cancer cell growth and/or survival was examined by siRNA experiments. Cellular invasive effect of CHODL on mammalian cells was examined by Matrigel assays.</p><p><b>Results:</b> Immunohistochemical staining revealed that strong positivity of CHODL protein was associated with shorter survival of patients with NSCLC (<i>P</i> = 0.0006), and multivariate analysis confirmed it to be an independent prognostic factor. Treatment of lung cancer cells with siRNAs against <i>CHODL</i> suppressed growth of the cancer cells. Furthermore, induction of exogenous expression of CHODL conferred growth and invasive activity of mammalian cells.</p><p><b>Conclusions:</b> CHODL is likely to be a prognostic biomarker in the clinic and targeting CHODL might be a strategy for the development of anticancer drugs. <i>Clin Cancer Res; 17(24); 7712–22. ©2011 AACR</i>.</p></div>